The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Fruquintinib vs. placebo in mCRC: Q-TWiST analysis from FRESCO-2
Sebastian Stintzing, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, shares a post-hoc Q-TWiST analysis of the Phase II FRESCO-2 (NCT04322539) trial to assess the quality-adjusted survival benefit of fruquintinib (F) + best supportive care (BSC) versus placebo (P) + BSC in heavily pretreated patients with refractory metastatic colorectal cancer (mCRC). The analysis, which partitioned survival time into health states, revealed a significant improvement in quality-adjusted time without toxicity (TWiST) with F + BSC (4.06 months) compared to P + BSC (1.92 months). The overall quality-adjusted time with F + BSC (Q-TWiST) was 2.04 months longer, demonstrating a clinically meaningful benefit in quality-adjusted survival. This supports the notion that fruquintinib contributes to improved quality of life without compromising safety in this patient population. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
